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431 AUGMENTATION OF ANTI-INFLAMMATORY EFFECTS OF
DEXAMETHASONE BY SUPPRESSING ABCB1 GENE
EXPRESSION
K. Honjo, K.A. Takahashi, O. Mazda, T. Kishida, N. Hiraoka, A. Inoue,
M. Saito, H. Inoue, J. Imanishi, T. Kubo. Kyoto Prefectural University of
Medicine, Kyoto, JAPAN
Purpose: To investigate whether ATP-binding cassette sub-family B
member1 (ABCB1) gene silencing in ﬁbroblast-like synoviocytes (FLSs)
by RNA interference enhances anti-inﬂammatory effects of dexametha-
sone (DEX) in vitro.
Methods: CIA was induced in Dark Agouti rats (8−10 weeks of age) by an
intradermal injection of an emulsion of bovine typeII collagen in Freund’s
adjuvant at the base of the tail. FLSs were isolated from synovium of
rat knee joints 14 days after immunization. FLSs were cultured with
various concentration of DEX (0–100 nM) for 4 hr in DMEM medium
with 1% fetal calf serum. In some experiments, in order to investigate
whether changes in ABCB1b gene expression affect the anti-inﬂammatory
performance of DEX, the cells were also transfected with 100 nM of small
interfering RNA (siRNA) targeted to ABCB1b (siABCB1b) 48 hr before
DEX treatment. Total RNAs were extracted from the cells, and mRNA
levels of ABCB1a/1b and Il-6 were determined using quantitative real-
time PCR.
Results: ABCB1b mRNA levels were approximately 4 fold of ABCB1a
in cultured FLS without any treatment (Fig 1), and then, siABCB1b
was used in the following experiments. With transfection of synthetic
siABCB1b, ABCB1b mRNA levels was reduced approximately 70% of that
in control cells (Fig 2). After treatment with DEX at concentration of 1, 10,
100 nM to FLS, the expression of Il-6 mRNA were inhibited to 81.0±24,
34.8±14, 22.1±3.2 (%), respectively, compared to control cells (Fig 3).
When transfection with siABCB1b was performed in combination with
DEX treatment (1, 10, 100 nM), Il-6 expression was markedly reduced to
51.7±5.0, 16.2±2.3, 14.8±2.7 (%), respectively (Fig 3).
Conclusions: ABCB1 gene encodes P-glycoprotein (P-gp), a pump
molecule which is a 170 kDa membrane glycoprotein and decreases
intracellular drug concentration by efﬂuxing them from the intracellular
space. Multidrug resistance are known to a major obstacle for suc-
cessful treatment of articular inﬂamation in rheumatoid arthritis (RA)
and can be caused by overexpression of P-gp. Glucocorticoids (GCs),
which is one of the substrates of P-gp, are widely used in the treat-
ment of inﬂammatory joints in Osteoarthritis (OA) and RA with severe
synovitis, when they are uncontrollable with oral medicine or intraar-
ticular injection of hyaluronan. Treatment with GCs is associated with
signiﬁcant dose-dependent side-effects such as obesity, diabetes, im-
mune suppression and osteoporosis. Thereby, it is essential for suc-
cessful treatment of joint inﬂammation that lower dose of GCs ad-
ministration exerts sufﬁcient anti-inﬂammatory effects on arthritic syn-
ovium. In this study, we elucidated that P-gp function in siABCB1b
transfected FLSs was down-regulated and this augmented the anti-
inﬂammatory effect of DEX. These ﬁndings suggest that targeted down-
regulation of ABCB1 gene by siRNA has the potential to reduce ther-
apeutic dosage of GCs in the treatment of inﬂammatory joints in
OA and RA.
Figure 1. ABCB1 gene expression in FLSs. Target mRNA was deter-
mined by real-time PCR. Expression levels of ABCB1a, and ABCB1b
were standardized by ABCB1a mRNA.
Figure 2. Gene silencing effect of siABCB1b (cells not treated with siRNA
as a control).
Figure 3. Inhibitory effects of DEX (at the concentration of 0, 1, 10,
100 nM) on Il-6 mRNA expression in FLS with or without transfection of
siABCB1b.
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KNEE SYNOVIOCYTES AND CHONDROCYTES
S. Meini, F. Bellucci, C. Catalani, P. Cucchi, S. Giuliani, C.A. Maggi.
Menarini Ricerche S.p.A., Florence, ITALY
Purpose: Bradykinin (BK) is a proinﬂammatory peptide whose effects are
mediated through the activation of B2 receptors expressed by several cell
types. Released BK during inﬂammatory conditions sensitizes sensory
neurons, thus producing pain, and activates cell signalling cascades
thus contributing to the maintenance of inﬂammation. The intra-articular
administration of the peptide B2 receptor antagonist icatibant can reduce
pain in knee osteoarthritis. We have recently presented the pharmaco-
logical proﬁle of MEN16132, a small non-peptide molecule endowed with
high antagonist afﬁnity for the human, guinea pig, and mouse B2 receptor,
which exhibits a long lasting inhibitory effect in preclinical in vivo models.
Aim of the current investigation was to characterize BK B2 receptors
and signalling in human knee synoviocytes (ﬁbroblast-like, HFLS) and
chondrocytes (HCCK) in order to determine the pharmacological proﬁle
of MEN16132 in comparison with icatibant.
Methods: HFLS (ECACC, 408−05a) and HCCK (Lonza, CC-2550) were
cultured according to providers instructions. Experiments were performed
with cells at conﬂuence plated onto 12-well (binding) or 24-well (func-
tional). Radioligand ([3H]BK) binding experiments (incubation time 2h
at 4ºC) were carried out to detect BK afﬁnity (KD) and the number
of binding sites (Bmax), and to evaluate the inhibitory constant afﬁnity
(Ki) of antagonists. Inositolphosphates (IP) accumulation experiments
(incubation time 1h at 37ºC) were performed as index of BK induced
phospholipase C activation and to determine the antagonists potency
(pKB). Data are expressed as mean±s.e.m. of 3 experiments, each in
triplicate.
Results: Saturation data obtained with increasing [3H]BK concentrations
(0.1−30 nM) indicated the presence of BK binding sites both in HFLS and
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HCCK the Bmax values being 121550±45550 and 84880±5380 sites/cell,
respectively. From these data the calculated KD values were 1.1±0.06
(HFLS) and 3.1±1.7 (HCCK) nM. Inhibition curves were performed with
antagonists (1 pM-1mM) or unlabelled BK at the [3H]BK binding (1.5 nM).
Ki values for BK were 0.93±0.12 (HFLS) and 0.83±0.12 (HCCK) nM.
Both antagonists displayed high afﬁnity values: MEN16132 Ki values of
1.35±0.05 and 1.75±0.35 nM in HFLS and HCCK, respectively, and icati-
bant was 3- to 5-fold less potent, Ki values being 4.6±1.7 and 8.8±2.9 nM.
BK induced IP accumulation both in HFLS (EC50 0.73±0.08 nM) and
HCCK (EC50 0.64±0.05 nM), and the induced maximal effect was 11±3
(HFLS) and 15±1.5 (HCCK) fold over the basal response. The antag-
onists potency was evaluated by preincubating cells with MEN16132
or icatibant at different concentrations (0.1 nM-10 mM) for 15min before
the agonist concentration-response curve (0.03 nM-100mM). Both antag-
onists displayed a concentration-dependent antagonism, by shifting to the
right the BK curve, but MEN16132 displayed a greater potency in respect
to icatibant. The calculated pKB values were 9.93±0.09 (HFLS) and
10.44±0.16 (HCCK) for MEN16132, and 8.1±0.03 (HFLS) and 8.2±0.16
(HCCK) for icatibant.
Conclusions: This is the ﬁrst study quantifying B2 receptors, the afﬁnity
and potency of BK and its antagonists in HCCK. Current data highlight
the pharmacological proﬁle of MEN16132 as a very potent bradykinin
antagonist, in respect with icatibant, both in HFLS and HCCK.
433 MOLECULAR AND CELLULAR MECHANISMS REGULATING
CROSS-TALK BETWEEN THE CYCLOOXYGENASE AND
LIPOXYGENASE BIOSYNTHETIC AXES
B. Zhai, Q. He, J. Di Battista. McGill University, Montreal, QC, CANADA
Purpose: Our principal objective is to deﬁne potential cellular and
molecular interactions between inﬁltrating mast cells/mast-cell derived in-
ﬂammatory mediators and resident human synovial ﬁbroblasts ultimately
contributing to disease pathophysiology.
Methods:
1. Cultured human synovial ﬁbroblasts (HSF) were obtained from
osteoarthritis-affected synovial membranes.
2. Western and Northern blot analyses were used to measure protein
and mRNA expression, respectively.
3. Transient transfection assays were employed to express activated
signaling molecules and/or dominant negative mutants and to analyze
the reporter luciferase activity. A Mek1/2 inhibitor is also included in
this reporter luciferase activity study.
4. Prostaglandin E2 and leukotriene B4 levels were quantiﬁed by ELISA.
5. Statistical analyses included Student’s T-test and ANOVA.
Results:
1. Leukotriene B4 stabilized cyclooxygenase-2 mRNA and cyclooxygen-
ase-2 protein levels in Il-1b-treated human synovial ﬁbroblasts, leading
to the increase of prostaglandin E2 production.
2. Leukotriene B4 stabilized cyclooxygenase-2 mRNA on post-
transcriptional level through the cyclooxygenase-2 mRNA 3′-UTR re-
gion in Il-1b-treated human synovial ﬁbroblasts. There is no transcrip-
tional regulation in this stabilization effect of leukotriene B4.
3. Leukotriene B4 exerts this stabilization through Raf/MEK1/ERK1/2
signaling pathway in Il-1b-treated human synovial ﬁbroblasts.
4. The AU-containing proximal region of cyclooxygenase-2 mRNA 3′-
UTR is more important for this stabilization effect of leukotriene B4
in Il-1b-treated human synovial ﬁbroblasts than more distal AU rich
sequences.
Conclusions: The pathogenic mechanisms responsible for arthritis re-
main poorly understood both systemically and in the microenvironment of
the diarthrodial joint. Mast cells are detected in the synovial membrane of
osteoarthritis patients. We demonstrate the potential cellular and molec-
ular interactions between mast cells and mast-cell derived inﬂammatory
mediators and resident human synovial ﬁbroblasts. We hypothesize that
mast-cell derived leukotrienes contribute to synovial inﬂammation through
stabilization of synoviocyte cyclooxygenase-2 expression.
434 ELECTROMAGNETIC FIELDS AND ADENOSINE RECEPTORS
IN CHONDROCYTES AND SYNOVIAL FIBROBLASTS
M. De Mattei1, K. Varani2, F.F. Masieri1, A. Ongaro1, F. Vincenzi2,
P.A. Borea2, A. Caruso1, M. Fini3, S. Setti4, R. Cadossi4. 1Department
of Morphology and Embriology, University of Ferrara, Ferrara, ITALY ,
2Department of Clinical and Experimental Medicine, University of
Ferrara, Ferrara, ITALY, 3Department of Experimental Surgery, Rizzoli
Orthopaedic Institute, Bologna, ITALY, 4Igea Clinical Biophysics, Carpi,
Modena, ITALY
Purpose: Inﬂammation plays an important role in promoting articular car-
tilage damage in joint diseases such as osteoarthritis (OA). Chondrocytes
and synovial ﬁbroblasts (SFs) are involved in joint inﬂammation by releas-
ing biochemical mediators (NO, prostaglandins) and pro-inﬂammatory
cytokines which lead to the decrease of chondrocyte anabolic activity
and the increase of extracellular matrix degradation. Therefore, to prevent
cartilage damage, therapies should aim both to enhance chondrocyte
anabolic activity and to control inﬂammation. Electromagnetic ﬁelds
(EMFs) stimulate anabolic activities in cartilage explants and prevent the
catabolic effect of the inﬂammatory cytokine Il-1. In vivo EMFs retard the
development of OA lesions in guinea pigs; in humans they have been
successfully used for the treatment of OA. Adenosine is known to reduce
inﬂammation in several models by interacting with four receptors (A1,
A2A, A2B and A3). The role of adenosine for managing joint inﬂammation
has been recently documented and drugs with adenosine A2A receptor
agonist activity have shown chondroprotective effects. The aim of this
study was to investiga the potential anti-inﬂammatory activities of EMFs
by the characterization of their effects on adenosine receptors in bovine
chondrocytes and SFs. The functional interaction among adenosine A2A
analogs and EMFs in SFs was analyzed by evaluating the production of
cAMP, an intracellular mediator, the release of prostaglandin E2 (PGE2)
and cyclooxygenase-2 (COX-2) expression.
Methods: Chondrocytes and SFs isolated from bovine articular joints
were cultured in vitro. The effects of EMFs (1.5 mT, 75Hz) on adenosine
receptors were investigated by saturation and competition binding experi-
ments. Adenylyl cyclase assays were performed to evaluate cAMP levels
induced by the A2A agonist, CGS 21680 (2-[p-(2-carboxyethyl)-phenetyl-
amino]-5′-N-ethyl-carboxamido adenosine) and the A2 agonist, NECA (5′-
N-ethyl-carboxamido adenosine) in the absence and in the presence of
EMFs. CGS 21680 and NECA were added to SFs untreated or treated
with TNF-alpha (10 ng/ml) in the absence or in the presence of EMFs.
PGE2 release was measured by immunoassay and COX-2 expression
was evaluated by RT-PCR.
Results: EMFs evoke the upregulation of the A2A and A3 receptors in
both SFs and chondrocytes. The increase in A2A receptor density (1.9 and
2.4 folds, p< 0.01 respectively in chondrocytes and SFs) was associated
to an increase in cAMP levels indicating the functionality of the receptors
in EMF-exposed cells. TNF-alpha stimulated PGE2 release in SFs. CGS
21680 and NECA signiﬁcantly inhibited PGE2 production respectively of
49% and 55%; EMFs inhibited PGE2 release of 63% (vs. TNF-alpha,
p< 0.01) and strongly enhanced the inhibition induced by the agonists.
Modiﬁcation of COX-2 expression mirrored changes in PGE2 levels.
Conclusions: This study supports anti-inﬂammatory activity of EMFs
mediated by an up-regulation of A2A receptors and shows a molecular
action mechanism by which EMFs act. The in vitro EMF anti-inﬂammatory
activity is consistent with the decrease in inﬂammatory cytokines expres-
sion in the articular cartilage of OA animals. Noteworthy, the biophysical
modulation of adenosine pathways has been used in humans as a
therapeutic intervention to control the inﬂammatory microenvironment in
in arthroscopic procedures.
435 ROLE OF HEME OXYGENASE-1 IN THE CONTROL OF HIGH
MOBILITY GROUP BOX CHROMOSOMAL PROTEIN 1 IN
OSTEOARTHRITIC SYNOVIOCYTES
I. Garcı´a-Arnandis1, I. Guille´n2, A. Bru3, M. Alcaraz1. 1University
of Valencia. Department of Pharmacology, Valencia, SPAIN,
2Cardenal-Herrera CEU University, Moncada, SPAIN, 3Department of
Orthopaedic Surgery and Traumatology, General Hospital, Valencia,
SPAIN
Purpose: The production of inﬂammatory mediators may contribute to
osteoarthritis (OA) pathology. High mobility group box chromosomal pro-
tein 1 (HMGB1) acts as a pro-inﬂammatory cytokine in a wide range of
cells and binds to the receptor for advanced glycation products (RAGE), a
pathway leading to catabolic responses in articular tissues. Of particular
interest in the regulation of inﬂammatory and catabolic processes is the
